Wim Wilpshaar
Overview
Explore the profile of Wim Wilpshaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kashiwagi A, Shestakova M, Ito Y, Noguchi M, Wilpshaar W, Yoshida S, et al.
Diabetes Ther
. 2019 Oct;
10(6):2201-2217.
PMID: 31606880
Introduction: Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). The objective of this pooled analysis was to characterise the...
2.
Shestakova M, Wilding J, Wilpshaar W, Tretter R, Orlova V, Verbovoy A
Diabetes Res Clin Pract
. 2018 Nov;
146:240-250.
PMID: 30391333
Aim: To assess the efficacy and safety of ipragliflozin as add-on therapy to metformin in Russian patients with type 2 diabetes mellitus. Methods: In this double-blind study conducted in 14...
3.
Fonseca V, Ferrannini E, Wilding J, Wilpshaar W, Dhanjal P, Ball G, et al.
J Diabetes Complications
. 2013 Jan;
27(3):268-73.
PMID: 23276620
Aim: To evaluate the efficacy, safety, and tolerability of multiple doses of ipragliflozin. This novel selective inhibitor of sodium glucose co-transporter 2 is in clinical development for the treatment of...
4.
Schwartz S, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W
Diabetes Technol Ther
. 2011 Aug;
13(12):1219-27.
PMID: 21854192
Background: The sodium-dependent glucose co-transporter 2 (SGLT2) is a high-capacity, low-affinity transport system primarily expressed in the renal proximal tubules, where it plays an important role in the regulation of...
5.
Marais A, Raal F, Stein E, Rader D, Blasetto J, Palmer M, et al.
Atherosclerosis
. 2007 Aug;
197(1):400-6.
PMID: 17727860
This study assessed the efficacy of rosuvastatin for reducing plasma low-density lipoprotein (LDL) cholesterol after 18 weeks of open-label, forced titration in patients with homozygous familial hypercholesterolaemia (hoFH) and compared...
6.
Fellstrom B, Holdaas H, Jardine A, Rose H, Schmieder R, Wilpshaar W, et al.
Kidney Blood Press Res
. 2007 Aug;
30(5):314-22.
PMID: 17671394
Background: Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). Aims: AURORA (A study to evaluate the Use of Rosuvastatin in subjects On...
7.
Stalenhoef A, Ballantyne C, Sarti C, Murin J, Tonstad S, Rose H, et al.
Eur Heart J
. 2005 Sep;
26(24):2664-72.
PMID: 16143705
Aims: The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients with the metabolic syndrome. Methods And Results: Patients with the metabolic syndrome with low-density lipoprotein cholesterol...
8.
Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, et al.
Curr Control Trials Cardiovasc Med
. 2005 May;
6(1):9.
PMID: 15910680
Background: Patients with end-stage renal disease (ESRD) are at high risk of cardiovascular events. Multiple risk factors for atherosclerosis are present in ESRD and may contribute to the increased risk...